Year archive

Innate Pharma — 2012 filings

All 46 regulatory filings released by Innate Pharma (IPH) in 2012, sourced directly from the official regulator.

46 Filings

2012 Period

2012 filings (46)

Filing	Released	Lang
Innate Pharma annonce son calendrier financier pour 2013 ainsi que ses prochains rendez-vous investisseurs Report Publication Announcement	2012-12-19	French
Innate Pharma announces its financial calendar for 2013 and its participation to upcoming investor conferences Report Publication Announcement	2012-12-19	English
Innate Pharma : Phase I clinical trial of IPH2102/BMS-986015 in combination with ipilimumab announced Investor Presentation	2012-12-19	English
Innate Pharma : Annonce d'un essai clinique de Phase I avec IPH2102/BMS-986015 en combinaison avec ipilimumab Regulatory Filings	2012-12-19	French
INNATE PHARMA (Euronext Paris: FR0010331421 - IPH) : Premier patient traité dans l'essai EffiKIR Regulatory Filings	2012-12-17	French
INNATE PHARMA (Euronext Paris: FR0010331421 - IPH): First patient treated in the EffiKIR trial Regulatory Filings	2012-12-17	English
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) annonce la publication de données relatives à quatre essais cliniques avec IPH2101 dans le myélome multiple Regulatory Filings	2012-12-11	French
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) updates on four early clinical trials with IPH2101 in Multiple Myeloma Regulatory Filings	2012-12-11	English
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) publie sa lettre aux actionnaires (N°10) Investor Presentation	2012-11-23	French
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) announces that its newsletter to shareholders (n°10) is now available Regulatory Filings Q3 2012	2012-11-23	English
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) annonce un chiffre d’affaires de 8,0 millions d’euros pour la période du 1er janvier au 30 septembre 2012, à comparer à 3,1 millions d’euros pour Interim / Quarterly Report 9M 2012	2012-11-14	French
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) announces revenue of 8.0 million euros for the first nine months of 2012, compared with 3.1 million euros for the same period in 2011. Earnings Release 9M 2012	2012-11-14	English
Rapport financier semestriel au 30 juin 2012 Interim / Quarterly Report H1 2012	2012-11-08	French
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) annonce sa participation au Salon Actionaria les 23 et 24 novembre au Palais des Congrès, pour la deuxième année consécutive AGM Information	2012-11-07	French
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) announces its second participation to Actionaria, a forum dedicated to meeting with individual investors, on November 23 & 24, in Paris Report Publication Announcement	2012-11-07	English
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) annonce qu’un essai clinique de Phase I sponsorisé par Bristol-Myers Squibb pour IPH2102/BMS-986015 a été publié sur le site du NIH clinicaltrial Regulatory Filings	2012-10-30	French
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH)today announces that a Phase I trial sponsored by Bristol-Myers Squibb was published on the NIH website ClinicalTrials.gov for IPH2102/BMS-986015 a Regulatory Filings	2012-10-30	English
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) annonce aujourd’hui ses résultats semestriels au 30 juin 2012 Earnings Release H1 2012	2012-09-06	French
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) announces today its financial results for the first half of 2012 Interim / Quarterly Report H1 2012	2012-09-06	English
Rapport financier semestriel d'Innate Pharma au 30 juin 2012 Interim / Quarterly Report H1 2012	2012-09-06	French
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) : Autorisation réglementaire pour un essai clinique de Phase II randomisé avec IPH2102 dans la leucémie aigüe myéloïde Regulatory Filings	2012-09-04	French
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) receives regulatory authorization to start randomized Phase II trial with IPH2102 in Acute Myeloid Leukemia Regulatory Filings	2012-09-04	English
BILAN DE FIN DU CONTRAT DE LIQUIDITÉ CONCLU AVEC NATIXIS, CONCLUSION D’UN NOUVEAU CONTRAT DE LIQUIDITÉ AVEC GILBERT DUPONT Share Issue/Capital Change	2012-09-03	French
SIGNING OF A LIQUIDITY CONTRACT WITH GILBERT DUPONT ENDING OF THE PREVIOUS LIQUIDITY CONTRACT WITH NATIXIS SECURITIES Regulatory Filings	2012-09-03	English
Innate Pharma SA publie le nombre d’actions composant son capital social ainsi que le nombre de droits de vote associés au 1er juillet 2012 Share Issue/Capital Change	2012-07-09	French
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) releases its total number of shares outstanding as well as its voting rights as at July 1, 2012 Share Issue/Capital Change	2012-07-09	English
Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces that its Annual General Meeting (“AGM”) took place on June 28, 2012, in Marseilles, France. All proposed resolutions at the AGM were voted Declaration of Voting Results & Voting Rights Announcements	2012-07-02	French
Innate Pharma SA (Euronext Paris : FR0010331421 – IPH) annonce que son Assemblée générale mixte s’est tenue à Marseille, le 28 juin 2012. Toutes les résolutions proposées ont fait l’objet d’un vote co AGM Information	2012-07-02	English
Innate Pharma SA(Euronext Paris : FR0010331421 – IPH) annonce la tenue de son assemblée générale annuelle le 28 juin prochain à Marseille AGM Information	2012-06-11	French
Innate Pharma (Euronext Paris: FR0010331421 – IPH) to hold its Annual General Meeting of Shareholders on June 28, 2012, in Marseilles, France AGM Information	2012-06-11	English
“L’immunologie et l’immunité innée, clés du traitement contre le cancer” telle est la conclusion de la table ronde qui a réuni un panel d’experts dont les deux prix Nobel de Médecine 2011 Regulatory Filings	2012-05-21	French
“Immunology and Innate Immunity are Keys to Cancer Treatment” Conclusions of the Roundtable of internationally renowned speakers, including winners of the 2011 Nobel Prize in Medicine Regulatory Filings	2012-05-21	English
Innate Pharma SA (Euronext Paris : FR0010331421 – IPH) annonce son chiffre d’affaires au 31 mars 2012 et fait le point sur sa trésorerie Earnings Release Q1 2012	2012-05-10	French
Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces its turnover for the first quarter of 2012 and updates on its cash position Earnings Release Q1 2012	2012-05-10	English
Document de référence et rapport financier annuel d'Innate Pharma Annual Report FY 2011	2012-04-26	French
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) annonce aujourd’hui le lancement d’Innate en Actions, Club des Actionnaires de la Société Regulatory Filings	2012-04-18	French
Bristol-Myers Squibb France et Innate Pharma annoncent l’organisation d’une table ronde exceptionnelle réunissant un panel d’experts autour du sujet : « L’immunité innée, de la découverte révolutionna Regulatory Filings	2012-04-16	French
Bristol-Myers Squibb France and Innate Pharma to host a roundtable event including internationally renowned panel speakers to discuss the topic «Innate immunity: from revolutionary discovery to revolu AGM Information	2012-04-16	English
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) annonce aujourd’hui ses résultats financiers pour 2011. Earnings Release FY 2011	2012-03-06	French
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) reports today its consolidated financial results for the year ended December 31, 2011. Earnings Release FY 2011	2012-03-06	English
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), la société de l’immunité innée développant des médicaments innovants contre le cancer et les maladies inflammatoires, annonce des produits opérat Earnings Release FY 2011	2012-02-07	French
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, reports higher annual revenue in 2011 Earnings Release FY 2011	2012-02-07	English
Un nouveau mécanisme de régulation du système immunitaire impliquant les cellules Natural Killer découvert par un des partenaires académiques majeurs d’Innate pharma et publié dans le magazine Science Regulatory Filings	2012-01-20	French
Novel immune regulation mechanism involving Natural Killer Cells described and published in Regulatory Filings	2012-01-20	English
Bilan semestriel du contrat de liquidité Innate Pharma avec la société Natixis Securities Capital/Financing Update	2012-01-02	French
Half-year report on Innate Pharma's liquidity contract with Natixis Securities Capital/Financing Update	2012-01-02	English

Filings by year

2026 40 filings
2025 135 filings
2024 136 filings
2023 150 filings
2022 124 filings
2021 123 filings
2020 67 filings
2019 127 filings
2018 50 filings
2017 50 filings
2016 74 filings
2015 51 filings
2014 55 filings
2013 37 filings
2012 46 filings
2011 38 filings
2010 41 filings
2009 50 filings
2008 9 filings